# Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

> **NCT04564703** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting European Myeloma Network** · enrollment: 160 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Iberdomide

## Key facts

- **NCT ID:** NCT04564703
- **Lead sponsor:** Stichting European Myeloma Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-22
- **Primary completion:** 2023-07-27
- **Final completion:** 2027-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564703, "Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04564703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*